Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor

Show full item record



Permalink

http://hdl.handle.net/10138/321187

Citation

Fontana , F , Fusciello , M , Groeneveldt , C , Capasso , C , Chiaro , J , Feola , S , Liu , Z , Mäkilä , E , Salonen , J , Hirvonen , J , Cerullo , V & Santos , H A 2019 , ' Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor ' , ACS Nano , vol. 13 , no. 6 , pp. 6477-6490 . https://doi.org/10.1021/acsnano.8b09613

Title: Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor
Author: Fontana, Flavia; Fusciello, Manlio; Groeneveldt, Christianne; Capasso, Cristian; Chiaro, Jacopo; Feola, Sara; Liu, Zehua; Mäkilä, Ermei; Salonen, Jarno; Hirvonen, Jouni; Cerullo, Vincenzo; Santos, Hélder A.
Contributor: University of Helsinki, Nanomedicines and Biomedical Engineering
University of Helsinki, ImmunoViroTherapy Lab
University of Helsinki, Division of Pharmaceutical Biosciences
University of Helsinki, ImmunoViroTherapy Lab
University of Helsinki, ImmunoViroTherapy Lab
University of Helsinki, Nanomedicines and Biomedical Engineering
University of Helsinki, Drug Research Program
University of Helsinki, Drug Research Program
University of Helsinki, Drug Research Program
Date: 2019-06
Language: eng
Number of pages: 14
Belongs to series: ACS Nano
ISSN: 1936-0851
URI: http://hdl.handle.net/10138/321187
Abstract: Recent approaches in the treatment of cancer focus on involving the immune system to control the tumor growth. The administration of immunotherapies, like checkpoint inhibitors, has shown impressive results in the long term survival of patients. Cancer vaccines are being investigated as further tools to prime tumor-specific immunity. Biomaterials show potential as adjuvants in the formulation of vaccines, and biomimetic elements derived from the membrane of tumor cells may widen the range of antigens contained in the vaccine. Here, we show how mice presenting an aggressive melanoma tumor model treated twice with the complete nanovaccine formulation showed control on the tumor progression, while in a less aggressive model, the animals showed remission and control on the tumor progression, with a modification in the immunological profile of the tumor microenvironment. We also prove that co-administration of the nanovaccine together with a checkpoint inhibitor increases the efficacy of the treatment (87.5% of the animals responding, with 2 remissions) compared to the checkpoint inhibitor alone in the B16.OVA model. Our platform thereby shows potential applications as a cancer nanovaccine in combination with the standard clinical care treatment for melanoma cancers.
Subject: ACETALATED DEXTRAN
ANTIGEN
BLOCKADE
CANCER-IMMUNOTHERAPY
DELIVERY
EFFICACY
IMMUNE CELLS
NANOPARTICLES
SURFACE-CHEMISTRY
TUMOR-CELL VACCINE
biohybrid
cancer vaccine
cell membrane
melanoma
microfluidics
nanotechnology
immunotherapy
porous silicon
immune checkpoint inhibitor
317 Pharmacy
221 Nano-technology
1182 Biochemistry, cell and molecular biology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Biohybrid_Vacci ... h_Checkpoint_Inhibitor.pdf 4.488Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record